Invivyd, Inc.

IVVD · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
129
SEC Filings

Business Summary

PART I . Overview Invivyd, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. We are devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2, the virus that causes COVID-19. PEMGARDA (pemivibart) is our first mAb to receive regulatory authorization and was designed to exert continuous pharmaceutical a...

Next Earnings

Q2 FY2026 — expected 2026-09-15

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionIVVDdiscussed_in_filing Cybersecurity
topic_mentionIVVDdiscussed_in_filing Cybersecurity
topic_mentionIVVDdiscussed_in_filing Regulation
topic_mentionIVVDdiscussed_in_filing Healthcare & Bio
topic_mentionIVVDdiscussed_in_filing Regulation
topic_mentionIVVDdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-052025-12-310001193125-26-092547EDGAR127K words
2025-03-202024-12-310000950170-25-042332EDGAR—
2024-03-282023-12-310000950170-24-037610EDGAR—
2023-03-232022-12-310000950170-23-009516EDGAR—
2022-03-312021-12-310000950170-22-005112EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001193125-25-268076EDGAR35K words
2025-08-142025-06-300000950170-25-109029EDGAR—
2025-05-152025-03-310000950170-25-071974EDGAR—
2024-11-142024-09-300000950170-24-126735EDGAR—
2024-08-142024-06-300000950170-24-096674EDGAR—
2024-05-092024-03-310000950170-24-057017EDGAR—
2023-11-092023-09-300000950170-23-062043EDGAR—
2023-08-102023-06-300000950170-23-041352EDGAR—
2023-05-112023-03-310000950170-23-021235EDGAR—
2022-11-102022-09-300000950170-22-024516EDGAR—
2022-08-152022-06-300000950170-22-017242EDGAR—
2022-05-132022-03-310000950170-22-009799EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-050001193125-26-092528EDGAR5K words
2026-01-080001193125-26-006997EDGAR—
2025-12-230001193125-25-329488EDGAR—
2025-11-240001193125-25-291992EDGAR—
2025-11-190001193125-25-288347EDGAR—
2025-11-060001193125-25-268057EDGAR—
2025-10-300001193125-25-258526EDGAR—
2025-10-060001193125-25-230898EDGAR—
2025-09-240001193125-25-215541EDGAR—
2025-08-220000950170-25-110952EDGAR—

129 total filings indexed. 102 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001832038
TickerIVVD
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 89cb00acded24f5b8cd9ba9d264121b466c8863dc08edcf000e281b51a31c675
parent: a8a1523ed7cac20e3a3cf7f9c90024442f2a1abb807627b720bdad77ef7c006f
content hash: 4688ec3deab38190eb213e2c4d9f1ceccbd3437f3a45dfd6ecc8057dc66571d9
signed: 2026-04-13T04:45:46.875Z
sources: 17 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf